DA Davidson analyst Linda Bolton Weiser maintains Tupperware Brands (NYSE:TUP) with a Buy and raises the price target from $38 to $41.5.
Immunic Reports New Data From Phase 2 EMPhASIS Trial Of Vidofludimus Calcium In Relapsing-Remitting Multiple Sclerosis Supporting The Drug’s Neuroprotective Potential
– Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening –
– Virtual Multiple Sclerosis R&D Day to be Held Today, November 17,